Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NQO2 | P16083 | 2/20 | 0.62 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15428085 | 0.92 | ALDH1A1 (0.73) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL6950433 | 0.91 | ALDH1A1 (0.70) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL16711695 | 0.89 | KDM4E (0.70) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL15428075 | 0.89 | KDM4E (0.81) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL15427778 | 0.88 | ALDH1A1 (0.63) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL16711874 | 0.87 | ALDH1A1 (0.60) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL18222560 | 0.85 | MTNR1A (0.78) | ALDH1A1POLBNQO2MTNR1AMTNR1B | |
| SCHEMBL15427786 | 0.85 | ALDH1A1 (0.62) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL16926284 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KDM4EPOLBHPGDMDM2 | |
| SCHEMBL3221458 | 0.81 | KDM4E (0.84) | ALDH1A1KDM4EPOLBHPGDMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376449-B2 | Indole carboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150203505-A1 | INDOLE CARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| WO-2014010602-A1 | INDOLECARBOXAMIDE DERIVATIVE | アステラス製薬株式会社 (JP) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203505-A1 | INDOLE CARBOXAMIDE DERIVATIVE | MTNR1A, MTNR1B, IDO2 | ALDH1A1 383/4885KDM4E 1577/4885POLB 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.